SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF

IL280103A1Pending Publication Date: 2026-08-01KAHR MEDICAL LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IL280103
Authority / Receiving Office
IL · IL
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-07-11
Filing Date
2019-07-11
Publication Date
2026-08-01
Estimated Expiration
2039-07-11

AI Technical Summary

Technical Problem

Current therapies fail to effectively activate immune cells to target and eliminate cancer cells due to the high expression of CD47 on tumor cells, which acts as an 'anti-phagocytic' signal, evading innate immune surveillance.

Method used

A SIRPa-4-1BBL fusion protein is developed, comprising a SIRPa amino acid sequence and a 4-1BBL amino acid sequence, capable of binding CD47 and activating the 4-1BB signaling pathway, thereby co-stimulating immune cells and enhancing phagocytosis of pathologic cells expressing CD47.

Benefits of technology

The SIRPa-4-1BBL fusion protein effectively targets and enhances the elimination of cancer cells by activating immune cells, including T cells and macrophages, within the tumor microenvironment, overcoming the immune evasion mechanisms employed by tumor cells.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

SIRPalpha-4-1BBL variant fusion proteins are provided. Also provided are isolated polypeptides comprising a SIRPalpha variant. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-41BBL fusion protein or the isolated polypeptide, host-cells expressing same and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art